The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.

[1]  J. Brugarolas,et al.  The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. , 2011, European urology.

[2]  B. Rini,et al.  Contrast enhanced CT (CE-CT) changes and nephrometry down-scoring of unresectable primary renal cell carcinoma (RCC) tumors in patients (Pts) treated with neoadjuvant sunitinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Berney,et al.  The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Ganser,et al.  Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients , 2011, World Journal of Urology.

[5]  B. Teh,et al.  Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. , 2010, The Journal of urology.

[6]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Robert G Uzzo,et al.  The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. , 2009, The Journal of urology.

[8]  Dongwoo Kang,et al.  A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients , 2009, Clinical Cancer Research.

[9]  E. Klein,et al.  Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. , 2009, The Journal of urology.

[10]  C. Blank,et al.  Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery , 2009, World Journal of Urology.

[11]  J. Patard,et al.  Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm , 2008, BJU international.

[12]  J. Haanen,et al.  Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response , 2008, Clinical Cancer Research.

[13]  J. Patard,et al.  Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. , 2008, European urology.

[14]  W. Meinhardt,et al.  The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. , 2002, European urology.

[15]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[17]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[18]  W. Linehan,et al.  Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. , 1999, The Journal of urology.

[19]  S L George,et al.  Reducing patient eligibility criteria in cancer clinical trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.